Skip to content

Moderna MRNA Short-Term Investments

Short-Term Investments at other companies

Pfizer logo
PfizerPFE
$11.37B-28.4%
Novavax logo
NovavaxNVAX
$561.97M+20.0%
ALN
Alnylam PharmaceuticalsALNY
$1.6B-8.3%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$238M-35.2%
Roivant Sciences logo
Roivant SciencesROIV
$2.87B+32.3%
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
$1.48B+11.4%

Other financials

Income statement

See full
Revenue$389.0M+260%
Gross profit-$566.0M-3,244%
Operating income-$1.4B-32.2%
Net income-$1.3B-38.3%
EPS (diluted)-$3.40-34.9%

Balance sheet

See full
Cash & equivalents$1.9B+17.4%
Total debt$1.3B+71.9%
Total equity$7.4B-26.4%
Total assets$11.5B-9.6%

Cash flow

See full
Operating cash flow-$630.0M+39.2%
CapEx$62.0M-47.0%
Free cash flow-$692.0M+40.0%

Valuation

See full
Market cap$21.62B+73.9%
Enterprise value$21.04B+76.5%
P/S9.7×+5.7×

Profitability

See full
Gross margin22.1%-32.0pp
Operating margin-153.3%+67.8pp
Net margin-143.6%+80.2pp
FCF margin-132.4%

Returns & leverage

See full
Return on equity-36.6%+11.9pp
Debt / equity0.2×+0.1×
Current ratio2.4×-1.8×

Where this comes from

Reported directly by Moderna in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Moderna’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Moderna's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Moderna's short-term investments?
Moderna (MRNA) reported short-term investments of $3.3B in Q1 2026.
How has Moderna's short-term investments changed year-over-year?
Moderna's short-term investments decreased by 24.2% year-over-year, from $4.35B to $3.3B.
What is the long-term trend for Moderna's short-term investments?
Over 5 years (2020 to 2025), Moderna's short-term investments has grown at a 10.1% compound annual growth rate (CAGR), from $1.98B to $3.2B.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.